NEW YORK, April 03, 2018 -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid" or the "Company") (NASADAQ:SLDB) and certain of its officers, on behalf of shareholders who purchased Solid securities (1) in Solid’s initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sldb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Solid’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) The company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sldb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Solid you have until May 28, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Anta Sports Expands Global Footprint With Strategic Puma Stake
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 



